X4 Pharmaceuticals (XFOR)
(Delayed Data from NSDQ)
$0.66 USD
-0.05 (-6.69%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $0.64 -0.02 (-3.40%) 6:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for X4 Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 114 | 122 | 82 | 79 | 126 |
Receivables | 1 | 1 | 1 | 1 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 6 | 5 | 4 | 1 |
Total Current Assets | 122 | 129 | 88 | 83 | 129 |
Net Property & Equipment | 1 | 1 | 2 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 17 | 17 | 17 | 27 | 27 |
Deposits & Other Assets | 1 | 1 | 2 | 3 | 2 |
Total Assets | 147 | 156 | 117 | 123 | 161 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 8 | 4 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 1 | 1 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 12 | 8 | 8 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 23 | 22 | 14 | 12 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 55 | 32 | 33 | 33 | 20 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 16 | 23 | 1 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 96 | 82 | 53 | 50 | 31 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 529 | 451 | 347 | 267 | 261 |
Retained Earnings | -478 | -377 | -283 | -194 | -132 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 51 | 74 | 64 | 73 | 129 |
Total Liabilities & Shareholder's Equity | 147 | 156 | 117 | 123 | 161 |
Total Common Equity | 51 | 74 | 64 | 73 | 129 |
Shares Outstanding | 167.20 | 121.60 | 24.70 | 16.30 | 12.40 |
Book Value Per Share | 0.31 | 0.61 | 2.61 | 4.47 | 10.42 |
Fiscal Year End for X4 Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 169 | 81 | 114 | 142 | 141 |
Receivables | 1 | 1 | 1 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 6 | 7 | 6 | 6 |
Total Current Assets | 175 | 87 | 122 | 148 | 148 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 28 | 17 | 17 | 17 | 17 |
Deposits & Other Assets | 2 | 1 | 1 | 1 | 1 |
Total Assets | 211 | 112 | 147 | 173 | 173 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 9 | 9 | 8 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 20 | 13 | 13 | 16 | 15 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 29 | 24 | 23 | 25 | 22 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 75 | 55 | 55 | 54 | 32 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 10 | 16 | 23 | 49 | |
Minority Interest (Liabilities) | 0 | 29 | 0 | 0 | 0 |
Total Liabilities | 116 | 111 | 96 | 106 | 106 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 533 | 531 | 529 | 526 | 524 |
Retained Earnings | -439 | -530 | -478 | -459 | -456 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 94 | 1 | 51 | 68 | 68 |
Total Liabilities & Shareholder's Equity | 211 | 112 | 147 | 173 | 173 |
Total Common Equity | 94 | 1 | 51 | 68 | 68 |
Shares Outstanding | 167.90 | 167.90 | 167.20 | 164.40 | 164.40 |
Book Value Per Share | 0.56 | 0.01 | 0.31 | 0.41 | 0.41 |